![Christer Nordstedt](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christer Nordstedt
Vorsitzender bei WNTRESEARCH AB
Profil
Christer Nordstedt is currently the Chief Executive Officer at Oblique Therapeutics AB, Chairman at Wntresearch AB, and Director at IRLAB Therapeutics AB.
He previously served as the Chief Executive Officer at Vivesto AB in 2022, Senior Vice President-Research & Development at Orion Oyj from 2017 to 2020, and Global Research Manager at Teva GmbH.
Nordstedt holds a doctorate degree from Karolinska Institutet, conferred in 1991.
Aktive Positionen von Christer Nordstedt
Unternehmen | Position | Beginn |
---|---|---|
WNTRESEARCH AB | Vorsitzender | 01.01.2022 |
IRLAB THERAPEUTICS AB | Direktor/Vorstandsmitglied | 01.01.2023 |
Orion Diagnostica AB | Direktor/Vorstandsmitglied | - |
Fermion Ltd. | Direktor/Vorstandsmitglied | - |
Snevringe AB | Vorsitzender | - |
Oblique Therapeutics AB
![]() Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Vorstandsvorsitzender | 01.12.2022 |
Ehemalige bekannte Positionen von Christer Nordstedt
Unternehmen | Position | Ende |
---|---|---|
VIVESTO AB | Vorstandsvorsitzender | 30.11.2022 |
ORION OYJ | Technik-/Wissenschafts-/F&E-Leiter | 05.03.2020 |
Teva GmbH
![]() Teva GmbH Medical DistributorsDistribution Services Part of Teva Pharmaceutical Industries Ltd., Teva GmbH is a German company that aims to provide high-quality medications to improve the quality of life for patients. The company is based in Ulm, Germany. The CEOs are Andreas Burkhardt, Thomas Andreas Schlenker. The company was founded in 2011 by Chaim Salomon, Günther Friedländer, Moshe Levinson, Yitschak Elstein. | Corporate Officer/Principal | - |
Ausbildung von Christer Nordstedt
Karolinska Institutet | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
ORION OYJ | Health Technology |
WNTRESEARCH AB | Health Technology |
VIVESTO AB | Health Technology |
IRLAB THERAPEUTICS AB | Health Technology |
Private Unternehmen | 5 |
---|---|
Teva GmbH
![]() Teva GmbH Medical DistributorsDistribution Services Part of Teva Pharmaceutical Industries Ltd., Teva GmbH is a German company that aims to provide high-quality medications to improve the quality of life for patients. The company is based in Ulm, Germany. The CEOs are Andreas Burkhardt, Thomas Andreas Schlenker. The company was founded in 2011 by Chaim Salomon, Günther Friedländer, Moshe Levinson, Yitschak Elstein. | Distribution Services |
Orion Diagnostica AB | |
Fermion Ltd. | |
Snevringe AB | |
Oblique Therapeutics AB
![]() Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Health Technology |